Search

Your search keyword '"Francesco Bono"' showing total 7 results
Start Over Author "Francesco Bono" Journal journal of the neurological sciences
7 results on '"Francesco Bono"'

2. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: Friend (fremanezumab in real world study), the first Italian multicenter, prospective real-life study

Author

Stefano Bonassi, Laura Di Clemente, Fabio Frediani, Antonio Carnevale, Francesco Bono, Florindo d’Onofrio, Cinzia Aurilia, Maurizio Zucco, Lucia Manzo, Massimo Filippi, Luisa Fofi, Maria Albanese, Claudia Altamura, Piero Barbanti, Fabrizio Vernieri, Carmelina Maria Costa, Roberta Messina, Gabriella Egeo, Paola Di Fiore, Stefania Proietti, and Bruno Colombo

Subjects
medicine.medical_specialty, Chronic Migraine, Neurology, business.industry, Medicine, Neurology (clinical), business, Psychiatry, Life study
Published
2021

3. Spread of segmental/multifocal idiopathic adult-onset dystonia to a third body site, data from the Italian dystonia registry

Author

Roberto Eleopra, Lucia Manzo, Alfredo Berardelli, Marcello Esposito, Laura Avanzino, Francesca Di Biasio, Luca Magistrelli, Carmen Terranova, Antonio Pisani, Anna Castagna, Alberto Albanese, Maurizio Zibetti, Salvatore Misceo, Marcello Romano, Paolo Girlanda, Marcello Mario Mascia, Roberto Ceravolo, Laura Bertolasi, Anna Rita Bentivoglio, Roberta Pellicciari, Maria Cotelli, Gabriella De Joanna, Cesa Scaglione, Giovanni Fabbrini, Maria Concetta Altavista, Tommaso Ercoli, Giovanni Defazio, Roberto Erro, Nicola Modugno, Giovanni Cossu, Daniela Cassano, Francesco Bono, Martina Petracca, Paolo Barone, Mario Coletti Moja, and Brigida Minafra

Subjects
Dystonia, Third body, Pediatrics, medicine.medical_specialty, Neurology, business.industry, medicine, Neurology (clinical), medicine.disease, business
Published
2021

4. Long-term (>48 weeks) safety and tolerability of erenumab in real-life

Author

Gabriella Egeo, Davide Bertuzzo, Adriana Fallacara, Maurizio Zucco, Roberta Messina, Antonio Carnevale, L. Di Clemente, Bruno Colombo, Claudia Altamura, Carmelina Maria Costa, Piero Barbanti, Massimo Filippi, Cinzia Finocchi, Angelo Pascarella, Fabrizio Vernieri, Sabina Cevoli, Maria Albanese, Nicoletta Brunelli, Paola Torelli, Bruno Mercuri, Francesco Bono, Marco Aguggia, Licia Grazzi, Luisa Fofi, Lucia Manzo, Michele Trimboli, Cinzia Aurilia, Paola Di Fiore, Valentina Favoni, Antonio Salerno, Fabio Frediani, Florindo d’Onofrio, and D. D’Amico

Subjects
medicine.medical_specialty, Abdominal pain, Constipation, Erythema, business.industry, Gastroenterology, Discontinuation, Chronic Migraine, Neurology, Tolerability, Internal medicine, medicine, In real life, Neurology (clinical), medicine.symptom, Adverse effect, business
Abstract

Background and aims: Erenumab proved to be safe and well tolerated in a 5-year continuation of a 1-year double-blind, placebo-controlled study. Aim: to assess >48-week erenumab tolerability and safety in a real-world setting. Methods: In this long term (>48-week), multicenter (n = 15), longitudinal cohort real life study, we monitored all the adverse events emerged in consecutive adult patients with high-frequency episodic migraine (HFEM) or chronic migraine (CM) treated with monthly erenumab 70 mg or 140 mg from 20 December 2018 to 15 December 2020. Results: 442 patients (HFEM: 115;CM: 327) were treated with erenumab for >48 weeks: 209 (47.3%) patients were treated for 49–60 weeks, 132 (29.9%) for 61–72 weeks;73 (16.5%) for 73–84 weeks;21 (4.7%) for 85–100 weeks. Overall, >1 treatment emergent adverse event (TEAE) was reported by 136 (30.8%) [HFEM: 43 (37.4%);CM: 93 (28.4%)]. Most common TEAE were constipation (n = 66;14.9%), injection site erythema (n = 15;3.4%), and influenza (n = 7;1.6%). Serious adverse events (SAE) were reported by 8 patients (1.8%) and led to treatment discontinuation: severe constipation (n = 3), abdominal pain (n = 1), NSTEMI (n = 3), Covid-19 infection (n = 1). Only severe constipation was considered treatment-related SAE (0.45%). Conclusions: Conclusion: Erenumab is safe and well tolerated also in long-term treatment (>48 weeks) in real life.

Published
2021

5. Long term (48-weeks) effectiveness, safety and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in real-world: The early 2 study

Author

Bruno Mercuri, Angelo Pascarella, Domenico D'Amico, Davide Bertuzzo, Adriana Fallacara, Claudia Altamura, Laura Di Clemente, Michele Trimboli, Cinzia Finocchi, Fabio Frediani, Antonio Carnevale, Gabriella Egeo, Antonio Salerno, Florindo d’Onofrio, Roberta Messina, Carlemina Maria Costa, Lucia Manzo, Sabina Cevoli, Francesco Bono, Marco Aguggia, Licia Grazzi, Maria Albanese, Massimo Filippi, Paola Torelli, Cinzia Aurilia, Nicoletta Brunelli, Luisa Fofi, Valentina Favoni, Paola Di Fiore, Bruno Colombo, Maurizio Zucco, Piero Barbanti, and Fabrizio Vernieri

Subjects
Pediatrics, medicine.medical_specialty, Chronic Migraine, Neurology, Tolerability, business.industry, medicine, Neurology (clinical), business, Term (time)
Published
2021

6. Italian botulinum toxin network recommendations for safe treatment of botulinum toxin infiltration during the COVID-19 pandemic: A video presentation

Author

Roberto Eleopra, Francesco Bono, and Maria Concetta Altavista

Subjects
2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), medicine.disease, Virology, Botulinum toxin, Article, Neurology, Pandemic, medicine, Neurology (clinical), Presentation (obstetrics), business, Infiltration (medical), medicine.drug
Published
2021

7. Limb dystonia due to complex regional pain syndrome: A case series

Author

Fabio Bombardieri, Giuseppe Magro, Francesco Bono, and Alessandro Mechelli

Subjects
Series (stratigraphy), medicine.medical_specialty, Complex regional pain syndrome, Physical medicine and rehabilitation, Neurology, business.industry, Medicine, Neurology (clinical), Limb dystonia, business, medicine.disease
Published
2021

Catalog

Books, media, physical & digital resources
See catalog results